Amber Salzman
Chief Executive Officer Epicrispr Biotechnologies
Amber Salzman, Ph.D., is Epicrispr’s chief executive officer and director. Dr. Salzman is a leader with more than 30 years of experience in the pharmaceuticals industry. Before joining Epicrispr, Dr. Salzman served as the president and CEO of Ohana Biosciences, pioneering the industry’s first sperm biology platform. Before Ohana, she served as the president and CEO of Adverum Biotechnologies and was a co-founder of Annapurna, SAS, where she served as president and CEO before its merger with Avalanche Biotechnologies to become Adverum. In that role, she saw the company’s stock price double.
Seminars
Thursday 26th March 2026
Designing Smarter Trials with External Controls & the Use of Digital Twins
4:00 pm
- Investigating how external controls and natural history data can support trial design when internal controls are not feasible
- Evaluating strategies for rare disease trials where there is variability of progression which needs to be quantified
- Understanding how trial design choices impact speed, cost, and regulatory success across biotech and pharma settings
